Genenta Science Shares Are Trading Higher After the Company Announced the Agenzia Italiania Del Farmaco Approved Its Phase 1 Trial for Metastatic Renal Cell Cancer for Its Flagship Product. Additionally, HC Wainwright & Co Reiterated a Buy Rating on...

Genenta Science股票交易走高，因公司宣佈意大利藥品管理局已批准其旗艦產品用於轉移性腎細胞癌的I期臨床試驗。此外，HC Wainwright公司重申了對該股的買入評級。

Benzinga · 10/03 01:07

Genenta Science Shares Are Trading Higher After the Company Announced the Agenzia Italiania Del Farmaco Approved Its Phase 1 Trial for Metastatic Renal Cell Cancer for Its Flagship Product. Additionally, HC Wainwright & Co Reiterated a Buy Rating on the Stock and Maintained Its $25 Price Target.

Genenta Science股價上漲，因公司宣佈意大利藥品監督管理局批准其用於轉移性腎臟細胞癌的一期試驗。此外，HC Wainwright & Co重申對該股的買入評級，並保持其25美元的目標價。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。